Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
12 hedge funds and large institutions have $21.6M invested in Anebulo Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 0 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
31% more capital invested
Capital invested by funds: $16.5M → $21.6M (+$5.06M)
0.07% more ownership
Funds ownership: 27.44% → 27.51% (+0.07%)
0% more funds holding
Funds holding: 12 → 12 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$40.9K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.5K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$4.6K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.6K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$8.48K |
| 2 |
PP
Praetorian PR
Rincon,
Puerto Rico
|
-$7.52K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
2L
1
22NW LP
Seattle,
Washington
| $15.5M | – | – | – |
|
|
LA
2
LVW Advisors
Pittsford,
New York
| $2.05M | – | – | – |
|
|
NCM
3
Nantahala Capital Management
New Canaan,
Connecticut
| $1.56M | – | – | – |
|
|
MP
4
Mangrove Partners
Greenwich,
Connecticut
| $1.22M | – | – | – |
|
|
PP
5
Praetorian PR
Rincon,
Puerto Rico
| $542K | -$7.52K | -2,713 | -2% |
|
|
IC
6
Ikarian Capital
Dallas,
Texas
| $504K | +$4.6K | +1,659 | +1% |
|
|
7
Vanguard Group
Malvern,
Pennsylvania
| $68.3K | +$17.5K | +6,312 | +39% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $63.7K | +$40.9K | +14,750 | +242% |
|
|
BFM
9
Boothbay Fund Management
New York
| $58K | +$4.6K | +1,659 | +10% |
|
|
10
BlackRock
New York
| $12.8K | -$8.48K | -3,060 | -42% |
|
|
11
Wells Fargo
San Francisco,
California
| $177 | +$3 | +1 | +2% |
|
ANEB Hedge Fund Activity: Q3 2023 in Review
12 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q3 2023, worth a combined $21.6M — up 31% from $16.5M a quarter earlier.
Fund positioning in ANEB was balanced in Q3 2023: 0 funds opened new positions, 0 closed out, 5 added to existing stakes and 2 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $40.9K. The largest seller was BlackRock, cutting an estimated $8.48K.
- 12 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $21.6M of Anebulo Pharmaceuticals stock for Q3 2023, up 31% quarter-over-quarter.
- 0 funds opened new Anebulo Pharmaceuticals positions in Q3 2023 and 0 closed out.
- The largest Anebulo Pharmaceuticals buyer in Q3 2023 was Tower Research Capital (TRC), an estimated $40.9K added.
- The largest Anebulo Pharmaceuticals seller in Q3 2023 was BlackRock, an estimated $8.48K sold.
Based on aggregated 13F filings for Q3 2023.